

Special Issue

Personalized Treatment for Heart Failure

Message from the Guest Editor

Heart failure (HF) is classified into three types based on left ventricular contractility (ejection fraction (EF)). HF-reduced EF has been established to be treated with many cardioprotective medications, including the fantastic four. On the other hand, cardioprotective medications that have evidence of HF mildly reduced EF (HFmrEF) and HF-preserved EF (HFpEF) are sodium/glucose cotransporter 2 inhibitors only, and their treatment is often difficult. Therefore, especially in these types of HF, it is also important to suppress their progression to the symptomatic HF stage (stage C HF). Hypertension (HT) is a major cause of decreased cardiac diastolic function in HFpEF, and blood pressure control is possible to suppress symptomatic HF; however, the mechanism behind this is poorly understood. The aim of this Special Issue is to bring new inspiration to daily clinical practice by discussing the mechanisms that induce HF in patients with HT. In this Special Issue, we are broadly soliciting reports on epidemiological studies and original research on HT and HF. Reviews are also welcome. We look forward to receiving your contributions.

Guest Editor

Dr. Shunsuke Kiuchi

Department of Cardiovascular Medicine, Toho University Faculty of Medicine, 6-11-1 Omorinishi, Ota-ku, Tokyo 143-8541, Japan

Deadline for manuscript submissions

10 August 2025



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/204603

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).